Table 1.
Relationship between TLR2 expression and clinicopathological features of BCa patients.
| Features | Total No. | TLR2 expression | P-values | |
|---|---|---|---|---|
| n = 150 | Low (n = 72) | High (n = 78) | ||
| Age (years) | 0.574 | |||
| ≤50 | 59 | 30 | 29 | |
| >50 | 91 | 42 | 49 | |
| Tumor size (cm) | 0.036* | |||
| ≤2 | 70 | 40 | 30 | |
| >2 | 80 | 32 | 48 | |
| ER status | 0.392 | |||
| Negative | 51 | 22 | 29 | |
| Positive | 99 | 50 | 49 | |
| PR status | 0.647 | |||
| Negative | 57 | 26 | 31 | |
| Positive | 93 | 46 | 47 | |
| HER2 status | 0.025* | |||
| Negative | 108 | 58 | 50 | |
| Positive | 42 | 14 | 28 | |
| Subtypes | 0.001* | |||
| Luminal A | 68 | 44 | 24 | |
| Luminal B | 42 | 12 | 30 | |
| HER2+ | 18 | 6 | 12 | |
| Triple-negative | 22 | 10 | 12 | |
| TNM stage | 0.030* | |||
| I–II | 95 | 52 | 43 | |
| III–IV | 55 | 20 | 35 | |
ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2;
P < 0.05.